
S-Alpha Therapeutics
Game-based digital therapeutics for pediatric myopia.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor | €0.0 | round | |
investor investor investor investor | €0.0 | round | |
investor investor investor investor investor investor investor | €0.0 | round | |
* | KRW11.0b | Series B | |
Total Funding | 000k |
Related Content
S-Alpha Therapeutics is a clinical-stage digital therapeutics company founded in Seoul, South Korea, in July 2019 by CEO Seung-Eun Choi and Chief Medical Officer Dr. Myung Joon Kim. The firm develops software-based, evidence-driven products to address diseases with significant unmet medical needs, combining medical knowledge with software technology. Its development pipeline covers therapeutic areas such as ophthalmology, neuropsychiatry, cancer, and immunology.
The company's business model revolves around creating clinically validated therapeutic interventions delivered through software, often in the form of interactive games. The lead product, SAT-001, is a game-based software designed to slow the progression of myopia (nearsightedness) in children. This product, which involves daily 30-minute sessions, aims to reduce the extension of the eyeball axis and provide an enjoyable, non-contact treatment option. S-Alpha is conducting clinical trials for SAT-001 in both South Korea and the United States. Other pipeline products include SAT-002 for mild cognitive impairment, SAT-003 for cancer cachexia, and SAT-008 for public health crises.
S-Alpha Therapeutics has successfully secured significant funding to advance its research and clinical trials. After an initial investment from LegoChem Biosciences in February 2020, the company raised $2.7 million in a seed round in November 2020. This was followed by a Series A round of $8.7 million in July 2021 and a Series B round of approximately $8.4 million in March 2023, bringing its total raised capital to over $18 million. Key investors include Korea Investment Partners, Hana Ventures, STIC Ventures, Stonebridge Capital, and CJ Investment.
Keywords: digital therapeutics, DTx, ophthalmology, myopia treatment, software as a medical device, SaMD, neuropsychiatry, clinical trials, pediatric myopia, health applications, cancer cachexia, cognitive impairment, life sciences, HealthTech, biotechnology